Following consent, patients will receive 15 fractions of radiotherapy to the affected breast
and to Axillary level III and SCV (Supra-Clavicular) lymph nodes, defined by CT imaging
obtained in a prone position using IMRT(intensity modulation radiation therapy ) technique:
one fraction daily for 5 days/week for 3 consecutive weeks. Patients will be seen for
follow-up at 45-60 days from first radiotherapy treatment, and then yearly. Patients will be
assessed for Lymphedema at baseline, end of treatment, and at yearly intervals after
completion of radiotherapy. All patients will be followed for toxicity and outcome (local and
systemic recurrence, survival). In addition, patients will complete a self-assessment of QOL
at baseline, week 3, day 45-60 and 2-yr follow-ups.